ECTRIMS 2019: Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab

Elisabeth Gulowsen Celius | ECTRIMS 2019 | SYYSKUU 12, 2019

Asiantuntija: Elisabeth Gulowsen Celius

Professor Elisabeth Gulowsen Celius present data from a study who examine over 8 years relapse rates before, during, and after the first pregnancy in alemtuzumab-treated patients. Over 8 years, 122 pregnancies met inclusion criteria; 72% of pregnancies began >12 months after the last alemtuzumab dose, 18% began >4 to 12 months after last dose, and 10% began ≤4 months after last dose. Click and hear the result.